// Press Article
Quanta Publishes Study in PLOS ONE
Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+
03 March 2020: Quanta Dialysis Technologies Ltd, a British medical technology innovation company, today announces that the peer-reviewed scientific journal PLOS ONE has published results from the Company’s investigations into a possible future development concept for its personal haemodialysis platform SC+. The publication reports on an ex vivo feasibility study showing enhancement of solute clearance using an experimental mode for pulsatile push-pull dialysate flow in a prototype variant of the SC+ device. This establishes feasibility that SC+ is potentially capable of delivering a therapy comparable to haemodiafiltration (HDF) without introducing additional complexity to the user.
Haemodialysis (HD) is based on diffusive clearance and is generally accepted as the standard of care for renal replacement therapy. HDF has been developed as an alternative form of therapy that adds convective flows to improve middle-molecular-weight clearance. Several studies suggest there may be clinical benefits to HDF; however, the additional complexity of managing an HDF treatment can create barriers making it burdensome for in-centre patients and inaccessible to self-care and home patients.
For this study, Quanta developed a prototype variant of SC+ that delivers convective flows equivalent to HDF without introducing any additional complexity to the user. Results from the study show that the pumping action generated by the prototype SC+ produced an enhancement of middle-molecular-weight clearance comparable with that achieved using pre-dilution HDF. Further studies are required to optimise device settings, but initial results show that SC+ has the potential to increase patients’ freedom of therapy choice without introducing additional complexity to their treatment.
We are pleased to announce the publication of this study in PLOS ONE. The results not only establish the feasibility that SC+ could deliver a therapy comparable to HDF, but also further demonstrate the versatility of SC+ for self-care and home haemodialysis applications.
Professor Clive Buckberry, Chief Technology Officer
John E. Milad, Chief Executive Officer, added: “Although this is only a feasibility study, it clearly demonstrates the exciting potential for SC+ to address future applications and additional clinical needs.”
The full paper entitled ‘Enhancement of solute clearance using pulsatile push-pull dialysate flow for the Quanta SC+: a novel clinic-to-home haemodialysis system’ is available online.